Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Net Cash Flow: 2020-2025

Historic Net Cash Flow for InMed Pharmaceuticals (INM) over the last 6 years, with Jun 2025 value amounting to $4.5 million.

  • InMed Pharmaceuticals' Net Cash Flow fell 76.50% to -$1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.7 million, marking a year-over-year increase of 164.62%. This contributed to the annual value of $4.5 million for FY2025, which is 292.42% up from last year.
  • As of FY2025, InMed Pharmaceuticals' Net Cash Flow stood at $4.5 million, which was up 292.42% from -$2.3 million recorded in FY2024.
  • In the past 5 years, InMed Pharmaceuticals' Net Cash Flow registered a high of $4.5 million during FY2025, and its lowest value of -$2.3 million during FY2024.
  • For the 3-year period, InMed Pharmaceuticals' Net Cash Flow averaged around $1.6 million, with its median value being $2.7 million (2023).
  • Its Net Cash Flow has fluctuated over the past 5 years, first slumped by 211.66% in 2022, then skyrocketed by 330.61% in 2023.
  • InMed Pharmaceuticals' Net Cash Flow (Yearly) stood at $1.1 million in 2021, then tumbled by 211.66% to -$1.2 million in 2022, then surged by 330.61% to $2.7 million in 2023, then slumped by 185.57% to -$2.3 million in 2024, then skyrocketed by 292.42% to $4.5 million in 2025.